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Abstract
Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter
significant delays before being tested in patients with cancer. While some of these delays have a scientific basis,
others do not. We need to do better. Innovative strategies need to move into early stage clinical trials as quickly as
it is safe, and if successful, these therapies should efficiently obtain regulatory approval and widespread clinical
application. In late 2009 and 2010 the Society for Immunotherapy of Cancer (SITC), convened an “Immunotherapy
Summit” with representatives from immunotherapy organizations representing Europe, Japan, China and North
America to discuss collaborations to improve development and delivery of cancer immunotherapy. One of the
concepts raised by SITC and defined as critical by all parties was the need to identify hurdles that impede effective
translation of cancer immunotherapy. With consensus on these hurdles, international working groups could be
developed to make recommendations vetted by the participating organizations. These recommendations could
then be considered by regulatory bodies, governmental and private funding agencies, pharmaceutical companies
and academic institutions to facilitate changes necessary to accelerate clinical translation of novel immune-based
cancer therapies. The critical hurdles identified by representatives of the collaborating organizations, now organized
as the World Immunotherapy Council, are presented and discussed in this report. Some of the identified hurdles
impede all investigators; others hinder investigators only in certain regions or institutions or are more relevant to
specific types of immunotherapy or first-in-humans studies. Each of these hurdles can significantly delay clinical
translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of
patients with cancer.
Introduction
Globally, cancer claimed an estimated 7.6 million lives in
2008 and is on pace to double that number by 2030 [1].
The impact of this disease on humanity is difficult to
measure. The Milken Institute estimates that in the Uni-
ted States (US) alone, a 1% reduction in cancer mortality
has an economic value of $500 billion [2]. Currently the
National Cancer Institute (NCI), National Institutes of
Health (NIH), foundations, governments, biotechnology
and pharmaceutical companies around the world are
investing substantially in research to conquer this disease.
Over the past decade, discoveries in basic cancer research
related to this investment have provided an enormous
number of insights, reagents, drugs and clinical protocols
with potential to significantly improve cancer outcomes.
Nowhere is this potential more striking and relevant to a
wide spectrum of human cancers than in research on
cancer immunotherapy, which has the capacity to pro-
vide durable clinical responses in even the most challen-
ging cancers. Nonetheless, the translation of these
discoveries from the “bench to the bedside” has been
painfully slow.
In an effort to accelerate translation of new develop-
ments in basic immunology into patients with cancer,
representatives from eight immunotherapy organizations
representing Europe, Japan, China and North America
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(Figure 1) convened an “Immunotherapy Summit” at the
24th Annual Meeting of the International Society for Bio-
logical Therapy of Cancer (iSBTc; now the Society for
Immunotherapy of Cancer, SITC). One of the concepts
raised by SITC and defined as critical by all parties was
the need to identify hurdles that impede effective transla-
tion of cancer immunotherapy. Subsequently, ten organi-
zations (Figure 2) met again in late 2010 at the 25th
Annual Meeting of SITC to discuss next steps and to
commit to regular conference calls. While this is an
important first step, identification of these hurdles is just
the beginning. The development of collaborative, interna-
tional working groups to identify solutions and help
remove these hurdles could increase the speed at which
novel, effective immunotherapy strategies reach patients
with cancer. That is the goal.
The hurdles identified by representatives of the (now fif-
teen) collaborating organizations (Figure 3) can be
grouped into nine general themes (Table 1). In some
instances an identified hurdle is substantially intercon-
nected with another hurdle or set of hurdles. For example,
the lack of validated biomarkers further complicates the
design and evaluation of clinical trials that combine immu-
notherapeutic agents. Thus efforts to address the identified
hurdles to the translation of cancer immunotherapy must
be through a coordinated, integrated, multidisciplinary
and international approach.
What is Cancer Immunotherapy? Cancer immunother-
apy is the original targeted therapy and includes any
strategy that utilizes the anticancer immune response or
components of the immune system, as cancer treatment.
Seventeen immunotherapy products have received FDA
approval in the past quarter century [3]. These include
non-specific stimulators, cytokines, monoclonal antibo-
dies, radiolabelled antibodies, immunotoxins, and cell-
based therapy (reviewed in [3]). Further, the recent
observations that immune response, characterized by
immunohistochemistry, has better prognostic power than
standard staging systems underscores the importance the
endogenous immune response plays in patient outcomes
and the potential impact boosting this immune response
has for increasing survival [4,5]. These findings may help
to recast the current classification, and to identify the
high-risk patients who would benefit the most from adju-
vant therapy.
1. Limitations of Preclinical Animal Models
While preclinical animal models have provided the basis
for our understanding of immune function and significant
insights into the mechanisms that regulate therapeutic effi-
cacy of immunotherapy, the current models have not been
consistent predictors for the efficacy of cancer immu-
notherapy strategies that enter the clinic. One reason for
this disconnect may be that small, transplantable tumors,
established for 3-5 days in an animal model, fail to recapi-
tulate the complex, integrated pathophysiological setting,
in which patients can have a large tumor burden that they
have lived with for months to years. Models that utilize
advanced or spontaneous tumors may begin to address
this shortcoming. Another limitation is the inherent
“immunogenicity” of the tumor model used. Experiments
with tumors expressing xenogeneic proteins are frequently
Figure 1 2009 Immunotherapy Summit at SITC creating the working group, National Harbor, MD, USA. Back row: Leif Haakason, Sylvia
Janetski, Franco Marincola, Lisa Butterfield, Hideaki Tahara, Dolores Schendel, F Stephen Hodi, Heinz Zwierzina, A. Raja Choudhury, Graham
Pawlec, Wenru Song. Front row: Tom Gajewski, Bernard A. Fox, Mary Disis, Michael Papamichail, Michael B. Atkins
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coupled with transgenic T cells to address basic questions
about T cell trafficking, cytokine profiles and clonal expan-
sion, in addition to many other scientific questions relevant
to understanding the immunological response to tumors.
However, given the foreign nature of the xenogeneic pro-
tein and the ease with which an immune response can be
generated against these targets in wild type (WT) mice,
these tumors are considered inadequate for modeling the
human immune response to immunotherapy strategies. In
other cases, the use of transplantable tumors without xeno-
geneic protein constructs may be useful. Further, many of
the frequently used tumor cell lines were generated 20 - 40
years ago; given the genetic drift possible in 100 genera-
tions, the inbred mice may exhibit substantial histocompat-
ibility differences that can result in these tumors being
more immunogenic today than when they were originally
developed, potentially limiting their usefulness as models of
human disease. Another limitation is that the vast majority
Figure 2 2010 Immunotherapy Summit at SITC, Capital Hill, Washington DC, USA. Back row: Michael Papamichail, Hideaki Tahara, Howard
Kaufman, Jedd Wolchok, Franco Marincola, James Finke, Rejean Lapointe, Hyam I. Levitsky, George Coukos, Wenru Song, Padmanee Sharma, F
Stephen Hodi, Jim Allison, Lisa Butterfield, William Murphy, Leif Haakson, A. Raja Choudhary, Heinz Zwierzina, Yutaka Kawakami, Kohzoh Imai.
Front row: Harpreet Singh-Jasuja, Michele Maio, Paolo Ascierto, Giorgio Parmiani, Bernard A. Fox, Axel Hoos, Tom Gajewski, Dolores Schendel,
Cedrik Britten.
Figure 3 2011 Immunotherapy Summit at SITC, North Bethesda, MD, USA. Back row: Michele Maio, Michael Papamichail, Michael
Nishimura, Bernard A. Fox, Andrea Nicolini, Jens-Peter Marschner, Tanja de Gruijl, Brad Nelson, Axel Hoos, Tetsuro Sasada, Yutaka Kawakami,
Rejean Lapointe, Christoph Huber, Jonathan L. Bramson, Pawel Kalinski, Paolo Ascierto, Giuseppe Masucci, Heinz Zwierzina, Franco Marincola, F
Stephen Hodi, Per Thor Straten, Jianda Yuan, Front row: Samir Khleif, Lisa Butterfield, Tom Gajewski, Graham Pawlec, Pam Ohashi, Cornelius
Melief, Cedrik Britten.
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of studies are done in genetically identical inbred animals
that do not represent the genetic diversity found in humans
or in young mice, lacking the impact of aging on the
immune system [6]. Some therapeutic interventions are
tested in human xenograft models in immune-deficient
mice, in which effects on and by the immune system are
not addressed [7]. Human xenograft models in which
human immune cells are also transferred are a potential
improvement [8], although the reality of a fully functional
human immune system in a mouse is still far away.
Recently, severely immunodeficient mouse strains have
been developed such as NOD.Cg-Prkdcscid IL2rgtmWjl/Sz
(NOD/SCID/IL-2Rgnull or NSG), which can be reconsti-
tuted with a human hematopoietic system through engraft-
ment of human cord blood CD34+ cells [9]. These offer
unique opportunities to study human grade immunomodu-
latory reagents. The development of spontaneous tumor
models in transgenic mice (in which animals are tolerant to
genes used to induce the malignant event) offer multiple
advantages over transplantable tumors for many applica-
tions. The tumors in models using genetically engineered
mice (GEM) often develop similar defects in the tumor
microenvironment, limiting host immune responses. More-
over, tumor growth is quite heterogenic mimicking human
tumors. The heterogenic phenotype of most GEM models
requires larger numbers of animals to be studied to assess
significance of the intervention. Unfortunately, the cost of
generating and maintaining transgenic colonies of GEM
can be prohibitive for many investigators. In addition, these
models are usually based on the tissue-specific expression
of a strong driver oncogene, which may overwhelm the
immune-surveillance and immune-editing steps of cancer
development. One example of an alternative approach to
integrate an oncogenic signal in tissue has been recently
reported [10]. Hydrodynamic co-delivery of genes encoding
b-catenin (CAT) and MET or AKT induced steatotic hepa-
tocellular adenomas that transitioned to hepatocellular car-
cinomas (HCC) or led to rapid induction of HCC,
respectively. This innovative approach overcomes many of
the afore mentioned limitations by providing a rapid and
relatively inexpensive method for generating spontaneous
tumors in mice of a specific MHC background, in specific
gene knock-out, transgenic, or aged mice. Together the
preclinical models remain an important “proving ground”
for some classes of immunotherapies and for the evaluation
of possible synergies with combination immunotherapies.
While imperfect, advanced and spontaneous tumor models
are still considered to be more useful than in vitro studies
at informing clinical trial designs of novel agents and com-
bination immunotherapy.
With regard to predicting safety of novel antigen-based
cancer immunotherapies by using animal models, numer-
ous limitations exist. Vaccination with antigens relies on
the species- (and allele-) specific binding of antigen to
human leukocyte antigen (HLA) receptors (in the case of
short peptide antigens) and species-specific processing of
antigens by a complicated interplay involving different
proteasome species, other proteases, heat shock proteins,
TAP transporter and finally, again, binding to HLA
receptor (in the case of protein, long peptide, RNA or
DNA vaccines). Even if mice were generated that
expressed the appropriate HLA type and the human anti-
gen sequences, such models might not adequately predict
safety or autoimmune effects based on the diversity of
the other components of antigen processing machinery
involved.
Preclinical animal studies have also been used to assess
potential toxicity of immunologically active agents. In the
absence of in vivo preclinical data, in-vitro assays have
been used to identify the ‘minimum anticipated biological
effect level’ (MABEL). A recent report offers a protocol
that provides increased sensitivity to detect soluble T cell
stimulants [11]. Alternatively, micro dosing or flat dose
escalation studies have been proposed. The lethal toxicity
associated with chimeric antigen receptor (CAR) gene-
modified T cells is an example where a preclinical model
did not exist to appropriately test the potential toxicity
[12,13]. The two reported cases led to both National
Institutes of Health (NIH) and the US Food and Drug
Administration (FDA) review and resulted in modifica-
tions to clinical trial design where the dose of adoptively
transferred gene-modified T cells is escalated from a
Table 1 Critical Hurdles in Cancer Immunotherapy Identified by SITC and Collaborating Associations
1. Limitations of current animal models to predict efficacy of cancer immunotherapy strategies in humans
2. Prolonged time to obtain approval to initiate clinical trials
3. Complexity of cancer, tumor heterogeneity and immune escape
4. Limited availability of reagents for combination immunotherapy studies
5. Limited funds available to translate science into patients
6. Lack of definitive biomarker(s) for assessment of clinical efficacy of cancer immunotherapies
7. Conventional clinical response criteria do not take into consideration differences between response patterns to cytotoxic agents and
immunotherapies
8. Paucity of teams of scientists and clinicians dedicated to translational research in cancer immunotherapy
9. Insufficient exchange of information critical to advancing the field
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much lower dose than where toxicity was observed. As
new agents and combinations of immunotherapies are
evaluated, flexibility of the regulatory agency providing
oversight will be critical for the efficient translation of
these strategies to patients.
Opportunities
Could standards be suggested for investigators using pre-
clinical models to improve the utility or interpretation of
animal studies? Are there other instances when proof-of-
concept studies in animals can be waived? Additionally,
the limitation of assessing toxicity of immunological
agents, specifically monoclonal antibodies, in non-human
primates has been raised at several SITC conferences.
These studies, due to their high cost, limit the number of
agents that are moved to the clinic. How often are such
studies instructive of clinical toxicities and when is it
appropriate to discuss with regulatory agencies the elimi-
nation of these studies?
2. Delayed Institutional, Administrative and Regulatory
Approval
The time to obtain approval to initiate a clinical trial has
been identified as a critical hurdle for some investigators.
In the global science community there are academic
institutions where administrative review can add as much
as seven months to the approval process. At other cen-
ters, thanks in part to standardized procedures and pro-
tocols, and institutional familiarity with the proposed
investigational strategies, administrative and institutional
review board (IRB) approval can be obtained relatively
quickly. Consistent with the difficulties perceived in the
U.S. to open trials, there has been a large movement of
cancer trials to Europe and Asia due to the slow activa-
tion of trials in the U.S.
With regards to regulatory approval within the US,
FDA reviewers must respond to the application for an
investigational new drug (IND) within 30 days of sub-
mission. While this efficient review process provides no
guarantee for rapid approval, the feedback that the
agency provides, sometimes prior to the 30 day window,
allows for modifications that can sometimes resolve
issues and avert a clinical hold on the application.
Health Canada employs the same 30 day rule for review
of clinical trials. Similarly, the European Medicines
Agency (EMA) has the option of an accelerated review
procedure for products of major therapeutic interest. In
contrast, regulatory agencies in some countries may take
a year or more to approve a comparable application.
Another major difference between nations is the dispar-
ity in production requirements for the biologics or drugs
used in the clinical trials. In the US, FDA exempts most
Phase 1 drugs, including biologics, to adhere to Current
Good Manufacturing Practice (cGMP) regulations [14]. In
contrast, the European Union has implemented a rule that
all early phase studies must be performed under GMP.
While the use of GMP in the European Union is thought
to have increased the quality of clinical trials, especially of
investigator-initiated trials, it has clearly added significant
cost and limited the capacity of many academic institu-
tions to perform translational cancer immunotherapy
trials.
Opportunities
A cost-benefit analysis of restrictions that limit transla-
tion of novel therapies to patients with advanced cancer
may be appropriate. Are there other processes, short of
GMP, that might be employed to increase quality but not
the cost of some early phase clinical trials? This is a parti-
cularly important issue since there is great variability in
access to facilities that function using cGMP and GMP
guidelines that also have the technologies available to
produce novel biologics developed by academia. Even
when a facility can be identified, traditional funding
mechanisms rarely pay for the production of the new
biologic.
3. Complexity of Cancer, Tumor Heterogeneity and
Immune Escape
Clearly cancer is a complex problem and this complexity
has been identified as a critical hurdle to the application
of cancer immunotherapy. The heterogeneity of the cells
making up the cancer and their propensity to develop
resistance to any form of therapy is well established
[15,16]. Further, histology results suggest that a specific
cancer, for example melanoma, is not a single disease,
but likely 13 or more different diseases [17], all of which
may ultimately be found to respond uniquely to thera-
peutic interventions [18]. Also, local stromal non-cancer
cells have a direct influence on tumor progression and
outcome [19], illustrating the complexity of tumor micro-
environment. In addition to the potential heterogeneity
within each tumor is the likelihood that tumor at each
metastatic site is heterogeneous in expression of antigens,
or lack thereof, and/or escape mechanisms; substantially
increasing the complexity of the disease in each patient
far beyond the simple categorization of that disease.
On top of the complexities directly related to the tumor
are variables that can influence a patient’s ability to gener-
ate and maintain an effective antitumor immune response.
A major factor in this setting is the overall immune status
of the patient. This is influenced by age, previous therapeu-
tic interventions as well as by elements directly and/or
indirectly related to the tumor. The status of the patient’s
immune system and its impact on clinical outcome has
important implications for the identification of host-related
prognostic markers, of host-related predictive markers to
classical chemotherapies and radiotherapies as well as that
of novel innovative immunotherapies. Unfortunately, there
is no consensus on a biomarker(s) for assessing immune
Fox et al. Journal of Translational Medicine 2011, 9:214
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status of individuals enrolling in immunotherapy trials [20],
however this should not prevent investigators from incor-
porating novel strategies to assess immune competence of
patients enrolling in trials. Recent reports suggest that the
immune signature at the tumor site, characterized by
genetic or histological assessment, may predict responsive-
ness to therapy [21,4]. Additional studies have also shown
that pre-surgical clinical trials can be used as a mode of
investigating the impact of immunotherapeutic agents on
human immune responses in both the systemic circulation
and tumor microenvironment, thus providing a feasible
platform on which to obtain crucial data that can then be
applied to larger clinical trials [22,23]. Support for these
types of Phase Ia or Phase IIa trials [24], which are
designed to investigate mechanisms and biologic end-
points, is necessary in order to identify potential biomar-
kers that correlate with benefit or resistance to therapy.
While additional validation is required, these observa-
tions are encouraging investigators to redouble their
efforts to assess immune competence of patients entering
immunotherapy trials. Also important to these efforts, is
the need to encourage testing of new agents in the neo-
adjuvant setting to allow improved assessment of poten-
tial biomarkers of early response.
Another level of complexity is the ability of cancer
cells, under the selective pressure of an antitumor
immune response, to shed targets or accessory molecules
in ways that allow them to evade detection and killing by
immune cells [25-27]. Alternatively, tumors may express
inhibitory molecules that impair the antitumor immune
response and limit the impact of the therapeutic inter-
vention. While the complexity of this problem is consid-
ered a critical hurdle, appreciating this complexity and
designing therapeutic combinations to augment immune
responses and neutralize escape mechanisms holds sub-
stantial promise for improving the effectiveness of cancer
immunotherapy.
Opportunities
Since the characterization of tumors prior to and follow-
ing immunotherapy has not been well studied, the con-
sortium might encourage a multicenter evaluation of
such specimens. This could include the development of a
taskforce to provide input on a global standardization of
the tumor microenvironment. In support of this concept
on October 24-25, 2012, SITC will provide opportunities
for the consortium to gather in North Bethesda for a
two-day workshop on evaluation of the tumor microen-
vironment. Performing systematic biopsies of tumor
lesions considered as representative targets should also
be considered and ethically admitted in most protocols
to allow a dynamic characterization of immunomodula-
tion. Further, modifications to some informed consent
documents should be considered to ensure that patient
specimens could be used to aid biomarker development.
Additionally, better identification of major immune
defects in patient groups may lead to more appropriate
therapies.
4. Limited Availability of Reagents for Combination
Immunotherapy Studies
While many preclinical studies have documented signifi-
cant synergies and improved outcomes when immu-
notherapy is combined with a wide range of agents, trials
with combined agents may present additional complex-
ities and risks to the drug developer and patient. One
problem is the classical method to find the maximum
tolerated dose (MTD) in phase I studies. Biological pro-
ducts, in particular vaccines, have less toxicity and may
have a bell-shaped dose immune response curve. This
has promoted the idea of dosing based on biological
activity assessed by a biomarker.
Opportunities
Developing a strategy that takes into consideration both
toxicity grade and the “immune response score” could
provide an optimal biologically active dose. While some
investigators are implementing such strategies into their
studies, consensus on this matter would likely aid the
implementation of combination immunotherapy trials.
It is becoming increasingly apparent that many stan-
dard cancer treatments may enhance the effectiveness of
immunotherapy, possibly due to increased inflammation,
release of antigen and danger signals, immunogenic cell
death pathways and dampening the effects of regulatory
cells. Indeed, many investigators are exploring immu-
notherapy combinations with other immunotherapeutic
agents, biologicals, targeted therapeutics, chemotherapy,
radiation and/or surgery as promising strategies to
improve cancer outcomes [28-32]. This enthusiasm has
been driven by the appreciation that even agents long
thought to work solely on tumor cells can have potent
effects on the anti-cancer immune response.
For agents that are already approved, the hurdle may
simply be limited resources or high costs necessary to
acquire the specified treatment for a combination study
unless the company marketing the product is willing to
supply the agent for the study. However, for agents that
are in early/late phase clinical trials and are not already
approved, pharmaceutical sponsors may not want the
added risk that the combination trial may interfere with
their drug development and registration plan. One con-
cern is that a novel strategy employing company A’s agent
X in combination with company B’s agent Y, may result in
a severe adverse event (SAE) that raises regulatory con-
cerns about either drug, X or Y, as a single regimen. This
may prompt additional patient safety monitoring require-
ments in all ongoing trials with drug X or Y, which pose
Fox et al. Journal of Translational Medicine 2011, 9:214
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particular challenges if either drug is in large, multi-
national registration trials. Given the SAEs that have been
observed with single agents (IL-2, anti-CTLA-4) and the
limited experience with combining immune-potentiating
biologicals, [33-35] there exists the possibility that combi-
nations may increase toxicity. However, the potential to
improve efficacy significantly, without concomitantly
increasing toxicity, as has been observed in preclinical and
a few clinical studies, provides a compelling rationale for
combining immune-potentiating agents. It is important to
continue the discussions in this area and try to agree upon
a compromise that will allow earlier testing of combina-
tions particularly in diseases that are in desperate need of
new therapies. Most cancers are not cured by one agent. It
is critical to take this into account and to work toward
developing a mechanism for testing combinations where
the scientific rationale supports the trial design.
Other concerns surround the possibility that investiga-
tors could discover something that might limit the utility
of that drug or obtain negative results that devalue intellec-
tual property (IP). Alternatively, mechanism of action stu-
dies may lead to broad claims by the investigators, further
limiting a company’s IP. Finally, integration of clinical and
regulatory operational efforts between two companies
poses challenges. These include selection of only one of the
companies or academic institutions to hold the IND and
assume full regulatory responsibility for a combination trial
as well as dissemination of all single agent IND safety
reports from each company to all investigators involved in
the combination trial. If these hurdles cannot be addressed,
it will take much longer to put together the “dream teams”
of immunological agents that many in our field are eager
to evaluate in the clinical setting based on synergisms
observed in preclinical studies. At the 2010 Collaboration
Summit on cancer immunotherapies hosted by SITC the
ten participating organizations agreed that promoting
innovative trials of combinations is a high priority. Late last
year the NCI took constructive action by launching the
Cancer Immunotherapy Network (CITN), providing a
mandate to develop and conduct clinical trials with priori-
tized immunotherapy agents alone or in rational combina-
tions [36-38]. While resources will be limited, the CITN
establishes a cooperative, multicenter framework to
advance a number of critical studies. But this is not
enough. More needs to be done to enable exploratory trials
of immunotherapy combinations.
Opportunities
One strategy may be to increase the number of academic
manufacturing facilities that could provide clinical grade
materials for clinical trials. Particularly for clinical grade
agents that large pharmaceutical companies are not inter-
ested in and that small biotech may not be able to distri-
bute to all the potential partners involved. This may be
particularly helpful for vaccine components such as
recombinant proteins, synthetic peptides, TLR agonists,
etc. One solution would be to have GMP facilities sup-
ported in academic institutions, for instance in the phar-
macy departments or faculties in universities or medical
centers. Another option would provide government con-
tracts to commercial laboratories to produce such pro-
ducts. Finally, governments might encourage corporations
to more actively pursue these strategies by offering patent
extensions or other incentives.
Recognizing the importance of promoting investiga-
tions of immunotherapy combinations, in March 2011
the CIC hosted its Annual Meeting with Focus on Sche-
dule and Dose for Combination Therapies and in April,
the CCIC also reviewed aspects of combination immu-
notherapy at their 4th annual meeting. Additional meet-
ings were held throughout 2011 with a focus on ways to
improve immunotherapy outcomes. In May, CIMT met
in Mainz, Germany, for their 9th Annual meeting entitled
“Targeting Cancer: Road-Maps for Success”. From June
30th until July 1st, The JACI met in Osaka for a sympo-
sium on the “Current status and future prospective of
cancer immunotherapy”. In September, CSCO and SITC
hosted a joint cancer immunotherapy session in Xiamen,
China, and in October, TIBT met in Jinan, China for
their “12th National Tumor Biotherapy Conference” and
ESCII and NIBIT joined together in Siena for “New Per-
spectives in the Immunotherapy of Cancer”. Also in
October, the PIVAC held their 11th meeting on cancer
vaccines in Copenhagen. In November, the SITC hosted
their second workshop on the science and logistics of
combination therapy [39] and in December, SITC joined
with NIBIT and the Italian Melanoma Intergroup in
sponsoring “Melanoma research: a bridge from Naples to
the World”. In 2012 additional meetings focused on can-
cer immunotherapy are planned. In March the BDA will
host their 11th Biological Therapy of Cancer Conference
in Munich and TVACT will host their 18th annual meet-
ing on Cancer Immunotherapy in Chicago. In April the
CIC will host their annual colloquium outside Washing-
ton DC and in May CIMT will host their 10th annual
meeting in Mainz. Early in 2012, the European Academy
of Tumor Immunology will start writing combinatorial
multicentric randomized Phase II trials associating aca-
demic GMP vaccines, immunogenic chemotherapy and
immune checkpoint blockade inhibitors so that multiple
institutions experienced in immunotherapy and immuno-
monitoring may be able to conduct this enterprise. While
each organization will continue to pursue meetings and
activities that address the needs of their members, the
consortium of fifteen organizations, termed the World
Immunotherapy Council, will work to find areas for col-
laboration and exchange of scientific information.
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5. Limited Funds Available to Translate Science into
Patients
Once investigators have identified a novel immunother-
apy treatment, with compelling preclinical evidence to
support its potential as a treatment for patients with
cancer, the challenge of obtaining funding to initiate the
clinical trial becomes a rate-limiting barrier. In the USA,
reduction in funding by the National Cancer Institute
(NCI) has seriously impacted the movement of new treat-
ment strategies to the clinic. The Department of Defense
has a number of programs that support translational clin-
ical trials and this has helped fill the gap. The struggling
biotech sector provides some help. In the USA some of
this is through the NIH-funded Small Business Innova-
tion Research (SBIR) and Small Business Technology
Transfer (STTR) programs that have provided needed
resources for moving agents to clinical trials. In other
instances it is local and state governments, angel inves-
tors and philanthropy, more than high risk-adverse
venture capital, that support these early phase trials. In
the future it is expected that these sources will continue
to play an important role in moving innovative first-in-
human studies, particularly of cellular and combination
immunotherapy studies, to patients with cancer. Investi-
gators in Europe, Canada and Japan are also concerned
about limited options to obtain support for translating
new immunotherapy strategies to the clinic. However,
the Japanese Ministry of Health, Labour and Welfare
recently announced a fund of 1.1 billion Japanese yen
for cancer vaccine clinical trials over the next 3 years.
In China, the new 12th 5 year plan will provide broad
support for translational clinical trials. Nonetheless, the
majority of investigators and co-authors consider the dif-
ficulty in obtaining funding to initiate clinical trials to be
a major hurdle for cancer immunotherapy.
Opportunities
To effectively communicate the impact investment in
translational research and biotechnology/cancer immu-
notherapy has on the economic development of national
and local economies as well as to human health [2].
6. Lack of Definitive Biomarkers of Immune Response
The lack of validated biomarkers for monitoring the devel-
opment of an immune response following therapy is
another critical hurdle for the translation of cancer immu-
notherapies. The iSBTc-SITC-/NCI/FDA Taskforce for
Immunotherapy Biomarkers, composed of nine societies
and participating organizations, has addressed this in detail
[20,14]. Eight of the nine challenges identified by this Task-
force were related to immunological monitoring considera-
tions. These included issues that should be optimized to
obtain validated assays that can provide a reliable platform
to compare cancer immunotherapy trials. A ninth
challenge related to the identification of biomarkers for
cellular immunotherapy products. These issues included:
1) Processing and storage of blood samples to bank
peripheral blood mononuclear cells (PBMC) and serum
for immunologic studies
2) Characterization of cellular products for therapy
3) Assay standardization and harmonization before
testing patient samples
4) Centralization of immunological monitoring
5) Standardized assays that should be used for clinical
trial antitumor immune response determination
6) How assay data should be analyzed for “responder”
and “non-responder” identification
7) Reporting immunological monitoring data in
publications
8) Validation of specific assays and/or analytes as bio-
markers of clinical response
9) Novel assays in development for immunological
testing of patients
Despite substantial efforts from many groups, immuno-
logical monitoring is challenged by two central limitations.
First, we do not know which parameters of immune
responses are the most important in a clinical response to
immunotherapy; secondly, we do not know which assays
or sample source (i.e., blood, lymph node, DTH site or
tumor) are optimal to assess these parameters and corre-
late to efficacy. Indeed, the tumor-specific cellular immune
response promoted by immunization often has not corre-
lated with clinical cancer regression [40,41]. A contribut-
ing reason may be the inherent complexity of immune
response assays, in conjunction with variable assay proto-
cols across clinical trial laboratories, which results in high
data variability and limited reproducibility [42]. Through
more than five years of community-wide proficiency
panels on the most commonly used immune response
assays (ELISPOT, HLA-peptide multimers, ICS and CFSE)
organized by the CIMT and CIC immune monitoring con-
sortia, it could be demonstrated that assay harmonization
is an effective mechanism to reduce these limitations
[42-44]. Harmonization guidelines resulting from this pro-
cess are simple to implement, do not impose standardized
assay protocols on individual laboratories and improve
assay performance without stifling scientific creativity.
Assay harmonization may provide a solution for non-vali-
dated biomarker assays to minimize data variability and
allow correlation of immune monitoring results with clini-
cal outcomes [45].
Another major hurdle in biomarker identification is the
low clinical response rates that limit identification of cor-
relates with response to immunotherapies. Indeed, when
response rates to immunotherapy reach 50%, it has been
possible to identify a significant correlation with objective
clinical response in patients maintaining at least 5%
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tumor-specific T cells in their peripheral blood for at least
two weeks [46]. Standardized immune monitoring of large
multi-institution trials has recently allowed for statistically
significant correlations of anti-tumor immunity and clini-
cal outcome [47].
Opportunities
Moving forward, the hurdles specified above will need to
be addressed. The report from the iSBTc-SITC/FDA/
NCI Taskforce on Immunotherapy Biomarkers [20]
builds on the NCI’s REMARK criteria [48] as well as
other more recent reports, e.g., MIFlowCyt, MIACA,
and MIATA [49-51]. Integration of standardized proce-
dures and internal controls as well as improved report-
ing practices will improve the ability to identify immune
biomarkers following immunotherapy and other
approaches which impact immunity. The group will
continue to promote discussion around the importance
of standardization and support educational programs
aimed at improving the ability to reproducibly assess
immunotherapy biomarkers.
7. Conventional Response Criteria May Not Reflect the
Patterns of Response to Immunotherapies
RECIST or modified WHO criteria have provided the
basis for evaluating whether patients with cancer respond
to therapy. These traditional criteria were developed for
cytotoxic therapies and evaluate reduction in tumor bur-
den following initiation of treatment. While immune
therapies have led to striking and rapid reductions in
tumor burdens in some patients, others have experienced
progression prior to experiencing tumor regression or
have had stabilization of disease. In these latter two
instances, patients may ultimately recognize a benefit in
overall survival but not be identified as responding to
therapy based on conventional response criteria. This
pattern of response to therapy has been observed by
many investigators but was not systematically captured
due to absence of adequate response criteria. In 2004, as
part of a collaboration between the iSBTc (now SITC)
and the CVC (now CIC) to address issues relevant to the
development of cancer immunotherapy, both organiza-
tions formed the Cancer Vaccine Clinical Trial Working
Group (CVCTWG), which included participation from
the FDA and NCI. CVCTWG held several workshops
between 2004 and 2005 with a concluding workshop
jointly hosted by CVC and SITC at the 2005 Annual
Meetings of both organizations. (http://www.sitcancer.
org/meetings/am05/workshop.php). These workshops
and the resulting publication with input from more than
180 investigators representing academia, NCI, FDA, and
the biotech and pharmaceutical sector, discussed how
evaluation of a clinical response to immunotherapy
might be modified from that for cytotoxic agents [52].
Following the 2005 meeting, both collaborative and
independent efforts of the CIC, CIMT and SITC took
place to continue addressing these issues. Involvement
from the NCI and FDA was included in many of these
discussions. The goal of these meetings was to: a) sum-
marize community knowledge, b) define challenges, and
c) offer directions for improvement through community
workshops. Resulting knowledge was used to systemati-
cally generate and analyze data to arrive at pertinent
improvements of conventional clinical endpoints. Four
main areas were addressed: 1) CIC and CIMT-CIP
immune monitoring proficiency panels including >80
international laboratories across the field defined harmo-
nization criteria to provide quality-control mechanisms
and minimize data variability without standardizing
laboratory protocols with the ultimate aim to allow for
correlation with clinical endpoints [42,43,51,44]. 2) The
SITC-FDA Taskforce on Immunotherapy Biomarkers,
with input from 9 organizations, addressed the lack of
validated biomarkers for monitoring the development of
an immune response following therapy and identified 9
challenges critical for the translation of cancer immu-
notherapies [20] (see section “Lack of Definitive Biomar-
kers of Immune Response”. 3) Clinical patterns of
antitumor response for immunotherapeutic agents are
more complex than those of chemotherapy [52-55] and
adjustments to RECIST or WHO criteria to capture all
patterns should be considered. 4) The translation of an
immune response into clinical antitumor activity and
possible survival benefit takes time [56,53,54]. Therefore,
effects on patient survival may only be detectable several
months after treatment start, which may be reflected in a
delayed separation of Kaplan Meier curves. This observa-
tion was made as part of a systematic review of publicly
available Phase 3 data from cancer immunotherapy trials
during a CVC workshop in 2006 [56]. The delayed
separation of Kaplan-Meier survival curves may be
addressed through revised statistical methods of non-
proportional hazards [54,57].
The core aspects of these community recommendations
were reviewed at a United States Food and Drug Adminis-
tration Workshop, which included participation and pre-
sentations by both CIC and SITC representatives, and
were included in a draft guidance document on “Clinical
Considerations for Therapeutic Cancer Vaccines” [58].
This illustrates how the collaborative efforts of commu-
nity-based organizations can lead to an expansion of
immunotherapy clinical trials methodology supporting
further advances in the field.
Opportunities
The discussion on changes to response criteria needs to
continue. A recent report used patient outcomes follow-
ing treatment with ipilimumab, a monoclonal antibody
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that blocks CTLA-4, to evaluate how proposed new
immune-related response criteria (irRC) compared to
RECIST or WHO criteria [55]. The important observa-
tions from that report were that four patterns of
response were all associated with favorable survival.
The four patterns of response to immunotherapy
were:
1) shrinkage in baseline lesions, without new lesions;
2) durable stable disease (in some patients followed by
a slow, steady decline in total tumor burden);
3) response after an increase in total tumor burden;
and
4) response in the presence of new lesions.
The conventional response criteria assumed that early
increase in tumor growth and/or development of new
lesions indicated progressive disease, which has become
synonymous with drug failure. For immunotherapeutic
agents, however, initial tumor growth or appearance of
new tumors does not necessarily reflect immunotherapy
failure nor long-term outcomes and survival. The new
irRC more accurately reflect the response patterns asso-
ciated with immunotherapies, and may permit more
comprehensive assessment of cancer immunotherapy
clinical trial results as well as provide guidance in the
clinical care of patients with cancer receiving immu-
notherapies. While these new irRC appear promising,
prospective evaluation of these criteria following treat-
ment with immune therapy is clearly warranted [57].
The FDA, who actively participated in many of these
discussions, agreed that cancer vaccines might require
considerable time in order to induce a therapeutic
response. To address this the FDA provided specific
recommendations for the clinical trial statistical analysis
plan in their “Draft Guidance for Therapeutic Cancer
Vaccines” [58]. It is important to note that the impact
on survival is still the gold standard employed by the
US FDA and that is the basis for the recent approval of
sipuleucel-T and Yervoy [44,59]. While recent reports of
markers of an immune response correlating with out-
comes are encouraging, substantial opportunities remain
for the development of novel surrogate markers of anti-
cancer immunity that correlate with improved survival
[47,60].
8. Paucity of Translational Teams of Scientists and
Clinicians
While there are centers of excellence with teams of inves-
tigators working to translate the latest technologies, there
are far too few for the number of diseases that need to be
targeted with promising immunotherapies. This needs to
be improved. Given the cost for drug development,
industry alone cannot be relied upon to conduct all the
early stage testing, particularly since academic transla-
tional investigator teams, close to both basic and clinical
science, are likely in the best position to move “their”
agent into the clinic. This requires an investment in
infrastructure. Depending on the class of agent(s) and
international setting, this may require simple clean
rooms or a complete GMP facility. The necessary infra-
structure, however, is not simply bricks and mortar, but
human capital as well. Teams including regulatory staff
for the substantial protocol and consent development
and approval steps, QA/QC support, trained data man-
agers and research nurses, in addition to clinicians and
scientists, are required to make this work. Clinicians
must be appropriately recognized for the time and energy
they spend participating in clinical trials beyond their
standard clinical duties (which are often more profitable).
A common sentiment is that there is a dramatic shortage
of clinicians with a commitment to clinical research.
This may be due to health systems that poorly valorize
involvement of clinicians in research. Another reason
clinicians may not have developed a career path in
immunotherapy may be linked to the previous negative
experience of cancer immunotherapy. Perhaps the
increasing momentum in the field will spark enthusiasm
for clinicians to train in this field. Another limitation is
the number of PhD scientists that are trained and
empowered to move their science to the clinic. Recogni-
tion of this, particularly by the Howard Hughes Medical
Institute (Med into Grad Initiative) and centers with NIH
Clinical and Translational Science Awards (CTSA) has
led to development of programs that are successfully tar-
geting incoming PhD students in hopes of developing
translational investigators [61]. But having clinical
researchers and translational PhD scientists alone is not
sufficient. The ability to organize, lead, motivate, meld
and sustain multidisciplinary groups of investigator in
translational teams is considered a critical hurdle for
advancing cancer immunotherapies and has been
recently discussed [62]. Recognizing the essential role
that team science plays in translational cancer immu-
notherapy, the SITC, in celebration of their 25th anniver-
sary, developed an award to recognize centers that have
excelled in this area and provided a significant and sus-
tained contribution over the past 25 years [63]. Another
signatory organization for this document, the Cancer
Research Institute, has been a sustaining source of sup-
port for the field of cancer immunology for close to
60 years. Its Pre-doctoral and Post-doctoral Fellowship
Programs have trained thousands of immunologists over
multiple generations. More recently through its partner-
ship with the Ludwig Institute for Cancer Research,
its Cancer Vaccine Collaborative establishes the needed
infrastructure, reagent procurement, clinical trials
management, and funding to carry out coordinated early-
phase clinical trials aimed at developing therapeutic
cancer vaccines.
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Opportunities
While the programs noted above provide a basis for
training and supporting team science, the majority of
Universities do not consider seriously these contributions
when evaluating candidates for promotion and tenure.
Recognizing the contributions of teams to the advance of
translational medicine and human health and developing
a structure for evaluating these contributions is an
opportunity for this consortium.
9. Need to Enhance Exchange of Information Critical to
Advancing the Field
Another component of this “team” hurdle is the
exchange of information. Given the increasing complex-
ity it is becoming less feasible for a single group to have
the detailed knowledge and resources to investigate,
analyze, select and implement the best strategies to
move forward in clinical trials for any given indication.
A possible solution to this hurdle may be to link clusters
of investigators with interest and experience with a
given tumor type. The histocompatibility/HLA field
might serve as an example for this concept. In that field,
participants from around the world supplied reagents,
ideas, practical work and shared projects to advance the
whole field of transplantation. As a whole, these investi-
gators made progress by helping the entire field through
specific input of work and resources, driving significant
advances over several decades. The success of these
interactions (workshops, exchanges, central repositories)
laid the foundation for bone marrow transplantation
and organ transplantation (kidney, heart, liver, lung), all
of which would not have been feasible through the
efforts of a single individual or organization, or even
one regional or national consortium.
Opportunities
The CITN may be able to promote a similar activity as it
brings together multiple groups under the same
umbrella. Similarly, societies, primarily those represented
by co-authors of this publication, could also play a role in
bringing together groups of like-minded investigators.
Through its annual meeting, associated programs and
other collaborative initiatives, the SITC is committed to
facilitating the exchange of information and education
among basic and translational researchers, clinicians, and
young investigators to advance cancer immunotherapies.
Importantly, SITC and the other signatory organizations
have initiated a process to join together and develop col-
laborative projects to catalyze continued success in can-
cer immunotherapy worldwide. This group, tentatively
designated the World Immunotherapy Council, will
begin by approaching some of the hurdles addressed in
this document, and also by organizing joint scientific
meetings and sessions.
Conclusion
The identification of nine critical hurdles (Table 1) is
an important beginning for this group of collaborating
organizations focused on cancer immunotherapy. In
late 2010, representatives of ten organizations met in
Washington D.C. to discuss the formation of interna-
tional working groups that can make recommendations
to address these hurdles, facilitate change and improve
the translation of novel immunotherapies to patients
with cancer. Through this international, collaborative
approach–marked by the establishment of the World
Immunotherapy Council–the many investigators and
the fifteen organizations involved in this initiative look
forward to combining their efforts synergistically to
accelerate the delivery of promising new cancer immu-
notherapies to patients around the world.
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